Immunologic responses to therapeutic biologic agents.
Recombinant protein technology and the subsequent development of biologic agents for pharmacotherapy have greatly improved the treatment of a wide variety of diseases in humans. These products are subject to reactions not previously seen in other drug classes. Additionally, subtle alteration in the manufacture or administration of a biologic agent may cause reactions in subjects who previously tolerated it. This review highlights the unique immunologic reactions that are associated with the more commonly used biologic agents.
Purcell
R T
RT
Division of Allergy/Immunology, Department of Internal Medicine, University of South Florida College of Medicine, James A. Haley Veterans' Administration Hospital, Tampa, Florida 33612, USA.
Lockey
R F
RF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology; D001691:Biological Therapy / Q000009:adverse effects* / Q000379:methods; D003001:Cloning, Molecular; D004342:Drug Hypersensitivity / Q000209:etiology* / Q000517:prevention & control; D066246:ErbB Receptors / Q000276:immunology; D006801:Humans; D007109:Immunity; D007328:Insulin / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000009:adverse effects / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D066246:ErbB Receptors; D007328:Insulin; D018719:Erb-b2 Receptor Tyrosine Kinases; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; C512478:EGFR protein, human; C508053:ERBB2 protein, human